| Sep 5 |
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
|
| Sep 4 |
Axsome migraine therapy undergoes FDA review again
|
| Sep 4 |
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
|
| Aug 27 |
Axsome Therapeutics to Participate in Investor Conferences in September
|
| Aug 21 |
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
|
| Aug 21 |
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
|
| Aug 16 |
Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double
|
| Aug 6 |
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
|
| Aug 6 |
BofA upgrades Axsome to buy, cites upcoming Auvelity data
|
| Aug 5 |
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
|
